Faraday Future Intelligent Electric Inc. (“Faraday Future” or the “Company”) (NASDAQ: FFIE), a California-based global shared intelligent electric mobility ecosystem company, today announced that on May 21, 2024, it received written notice from The Nasdaq Stock Market (“Nasdaq”) indicating that the Company’s failure to timely file the Quarterly Report on Form 10-Q for the period ended March 31, 2024 (the “Form 10-Q”) could serve as an additional basis for the delisting of the Company’s securities from Nasdaq under Nasdaq Listing Rule 5250(c)(1).

Delivered positive comparable restaurant revenue in the first five weeks of the second quarterLaunched new loyalty program on May 22ndRepaid approximately $21.2 million of debt ENGLEWOOD, Colo., May 29, 2024 /PRNewswire/ -- Red Robin Gourmet Burgers, Inc. (NASDAQ: RRGB) ("Red Robin" or the "Company"), a full-service restaurant chain serving an innovative selection of high-quality gourmet burgers in a family-friendly atmosphere, today reported financial results for the fiscal first quarter ended April 21, 2024.

AST SpaceMobile, Inc. (“AST SpaceMobile”) (NASDAQ: ASTS), and Verizon (NYSE, NASDAQ: VZ) today announced a strategic partnership with a commitment of $100 million from Verizon, to provide direct-to-cellular AST SpaceMobile service when needed for Verizon customers.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced preclinical data supporting the potential of ATA3219, an allogeneic, anti-CD19 chimeric antigen receptor (CAR) T-cell therapy candidate for the treatment of B-cell driven autoimmune diseases. Findings demonstrate that ATA3219 maintains comparable cytotoxic function and potency while inducing lower levels of pro-inflammatory cytokines compared to autologous benchmark CD19 CAR T cells. The data will be presented in a poster session at the International Society for Cell & Gene Therapy ...